[{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Abiogen Pharma S.p.A","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Acquisition","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Abiogen Pharma S.p.A"},{"orgOrder":0,"company":"EffRx Pharmaceuticals","sponsor":"Radius Health","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Alendronate Sodium","moa":"Osteoclast","graph1":"Musculoskeletal","graph2":"Approved FDF","graph3":"EffRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"EffRx Pharmaceuticals \/ Radius Health","highestDevelopmentStatusID":"15","companyTruncated":"EffRx Pharmaceuticals \/ Radius Health"},{"orgOrder":0,"company":"Peking Union Medical College Hospital","sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase IV","graph3":"Peking Union Medical College Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Peking Union Medical College Hospital \/ CSPC Ouyi Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"University Hospital Ghent","sponsor":"Amgen Inc | EffRx Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"University Hospital Ghent","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Oral Tablet, Effervescent","sponsorNew":"University Hospital Ghent \/ Amgen Inc | EffRx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"University Hospital Ghent \/ Amgen Inc | EffRx Pharmaceuticals"},{"orgOrder":0,"company":"Merck & Co","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Alendronate Sodium","moa":"Farnesyl diphosphate synthase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Merck & Co","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Merck & Co \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Merck & Co \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Binosto

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Undisclosed

                          Study Phase : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 28, 2010

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Dr Reddy Company Banner

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 14, 2025

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the agreement, EffRx will grant Radius an exclusive, royalty bearing license to Binosto (alendronate sodium), an effervescent tablet for oral solution indicated for osteoporosis in postmenopausal women and to increase bone mass in men with osteopor...

                          Product Name : Binosto

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 19, 2023

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Radius Health

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          04

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Through the acquisition, Abiogen gets Effrx's Binosto (alendronate sodium), an effervescent tablet for the treatment of osteoporosis. It will allow Abiogen to continue developing on Effrx's bisphosphonates family of molecules that in the area of ​​os...

                          Product Name : Binosto

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          May 29, 2023

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Approved FDF

                          Sponsor : Abiogen Pharma S.p.A

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          05

                          Peking Union Medical College Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Peking Union Medical College Hospital

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 04, 2021

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : CSPC Ouyi Pharmaceutical Co., Ltd

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          University Hospital Ghent

                          Country arrow
                          EPSC
                          Not Confirmed

                          University Hospital Ghent

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 27, 2020

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase II

                          Sponsor : Amgen Inc | EffRx Pharmaceuticals

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 10, 2018

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Phase II

                          Sponsor : Amgen Inc

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          November 05, 2015

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          University College Dublin

                          Country arrow
                          EPSC
                          Not Confirmed

                          University College Dublin

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Study Phase : Phase IV

                          Sponsor : Health Research Board, Ireland | Royal College of Surgeons, Ireland | Mater Misericordiae University Hospital | Beaumont Hospital | Rush University Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          December 22, 2014

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Phase IV

                          Sponsor : Health Research Board, Ireland | Royal College of Surgeons, Ireland | Mater Misericordiae University Hospital | Beaumont Hospital | Rush University Medical Center

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Unity Health Toronto

                          Country arrow
                          EPSC
                          Not Confirmed

                          Unity Health Toronto

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 24, 2013

                          Lead Product(s) : Alendronate Sodium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : CIHR Canadian HIV Trials Network

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank